Sir,
Available evidence suggests that anti-depressant treatment can precipitate mania or hypomania in bipolar patients (Wehr and Goodwin, 1987) . This is thought to be related to an increase in the neurotransmitters norepinephrine and/or dopamine (Bunny et al., 1972) . Recently interest has focused on mania induced by fluoxetine, a selective inhibitor of serotonin reuptake. Here we report on a case with fluoxetine induced mania in an adolescent and discuss some of the possible implications.
Case Report: Mr. A, a 15-years-old boy was brought to us with two-and-a-half month history of sadness, disturbed sleep with early morning awakening, reduced appetite, constipation, slowness, worries about examination and multiple somatic complaints. He was treated with gradually increasing doses of amilryptiline over the last one month. On a dose of ] 50 mg/day he developed severe blurring of vision and urinary retention, requiring drug discontinuation. There was no past or family history of psychiatric illness. Developmental history was normal. His mother died of gastric carcinoma when he was three-years-old. On examination he had reduced psychomotor activity, depressed mood, hopelessness, helplessness, and suicidal ideas. A diagnosis of major depressive disorder was made and fluoxetine 20 mg/day was prescribed.
He showed dramatic improvement and was euthymic by the sixth day of treatment. Two days later he did not sleep the whole night and from morning was found to be cheerful, overactive, and overtalkative. He had a reduced need for sleep and made big plans. The severity of the symptoms necessitated hospitalization and treatment initially with thioridazine (upto 300 mg/day) and later haloperidol (10 mg/day). Lithium carbonate was added and on 1200 mg/day, the serum level was 0.8 mmol/L. He became euthymic and was discharged after 4 weeks.
Five months later he was again hospitalized with a manic relapse. Following irregular lithium intake he developed insomnia followed by manic symptoms. He was first treated with a combination of lithium (1200 mg/day) and carbamazepine (upto 1000 mg/day) for one month. Then haloperidol (upto 40 mg/day) was added and continued for another month. Finally he showed a good response to a course of 8 ECT's. Now for the last three months he is maintaining well on lithium and carbamazepine treatment.
DISCUSSION
Our case showed a manic switch on day 9 of fluoxetine treatment. The first symptom noticed was loss of sleep. Wchr (1989) drew attention to the possible role of sleep loss as a trigger factor in the pathogenesis of mania. Insomania is more frequently reported with fluoxetine than with other tricyclics (Cooper, 1988) . The second episode also followed insomnia due to missed doses. Thus sleep loss may be an important mediating factor in the process of switch to mania. Antidepressantinduccd mania also coincide with the natural history of bipolar disorders. Post and Weiss (1989) have shown that pharmaco-responsivity may differ as a function of the stage of evolution of the kindling process. The fact that the same or another antidepressant may not induce mania at one point of time but may do so at a later stage may have relevance to the biology of bipolar disorder.
